UCB : Une avance sur sa guidance 2021, un S2 21 tournée autour de la clinique
>Un très solide S1 21 - UCB publie un très bon S1 2021, 3.5% au-dessus des attentes sur les revenus, 4% au-dessus de l’EBITDA courant et 10% au-dessus des attentes sur le BPA. Les revenus progressent de 7% à changes constants tirés par le momentum toujours fort des produits Core du groupe avec Vimpat (+9% à tcc), Cimzia (+11%) et Keppra (+23%). Ce sont les ventes de ce dernier qui expliquent la principale différence avec les attentes. Keppra a notamment été boosté par...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.